VARDENAFIL Drug Patent Profile
✉ Email this page to a colleague
When do Vardenafil patents expire, and when can generic versions of Vardenafil launch?
Vardenafil is a drug marketed by Alembic, Macleods Pharms Ltd, Crossmedika Sa, Stevens J, Teva Pharms, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in VARDENAFIL is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vardenafil
A generic version of VARDENAFIL was approved as vardenafil hydrochloride by TEVA PHARMS on May 3rd, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VARDENAFIL?
- What are the global sales for VARDENAFIL?
- What is Average Wholesale Price for VARDENAFIL?
Summary for VARDENAFIL
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 8 |
| Drug Prices: | Drug price information for VARDENAFIL |
| DailyMed Link: | VARDENAFIL at DailyMed |
US Patents and Regulatory Information for VARDENAFIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | VARDENAFIL HYDROCHLORIDE | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 208324-001 | Nov 16, 2018 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Teva Pharms | VARDENAFIL HYDROCHLORIDE | vardenafil hydrochloride | TABLET;ORAL | 091347-001 | May 3, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zydus Pharms | VARDENAFIL HYDROCHLORIDE | vardenafil hydrochloride | TABLET;ORAL | 208960-003 | Oct 31, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Crossmedika Sa | VARDENAFIL HYDROCHLORIDE | vardenafil hydrochloride | TABLET;ORAL | 209057-001 | Oct 31, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
